At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 27, 2026 at 07:10 ET
Armata Pharmaceuticals appointed Dr. Daniel Gilmer, a biopharmaceutical commercial executive with experience at Pfizer and McKinsey, to its Board of Directors. The move adds expertise in commercialization of anti-infectives, including leadership in the U.S. launch of PAXLOVID, to support Armata's development of bacteriophage therapeutics.
- Dr. Daniel Gilmer, Ph.D., appointed to Board of Directors effective April 24, 2026
- Gilmer previously served as Senior Director, Commercial Quality U.S. Team Lead at Pfizer since February 2025
- He led the U.S. launch of PAXLOVID and has experience in commercial strategy, patient access, and antimicrobial resistance
- Gilmer is an equal co-inventor on the patent for Exebacase, a first-in-class bacteriophage lysin
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access